The Brazil Point-of-Care Molecular Diagnostics Market was valued at $51.7 Million in 2025 and projected to reach to $85.8 Million by 2030, representing a compound annual growth rate of 10.7%. Brazil's point-of-care molecular diagnostics market is positioned for sustained growth as healthcare providers prioritize rapid, accurate diagnostic capabilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil's point-of-care molecular diagnostics market is valued at USD 51.7 million in 2025, with a projected CAGR of 10.7% through 2030, reaching USD 85.8 million by forecast end.
Brazilian healthcare facilities are increasingly adopting rapid molecular testing solutions to enhance diagnostic speed and accessibility across both urban centers and emerging regional markets.
Rising infectious disease prevalence and the need for rapid diagnostic capabilities are primary drivers of market expansion in Brazil, supporting adoption of point-of-care molecular technologies.
Brazil's diverse geography creates demand for decentralized diagnostic solutions, with point-of-care molecular testing enabling faster results in remote and underserved healthcare regions.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Offers point of care molecular diagnostic platforms and assay kits for infectious disease detection in hospitals and clinics | Rapid and accurate results, supports decentralized testing, high sensitivity and specificity, streamlined workflow, enables timely clinical decision-making, scalable for high patient volumes |
|
|
Provides POC molecular testing solutions for infectious diseases, including respiratory, gastrointestinal, and sepsis diagnostics | Broad pathogen coverage, fast turnaround time, easy-to-use systems for near-patient testing, reliable results, supports outbreak management and infection control |
|
|
Supplies compact and integrated POC molecular diagnostic platforms for infectious disease detection | High accuracy and reproducibility, supports multiplex testing, automated sample-to-result workflow, reduces turnaround time, improves early detection and patient management |
|
|
Offers portable POC molecular testing instruments and assay kits for infectious diseases, including respiratory and sexually transmitted infections | Quick results at or near the patient, user-friendly interface, high sensitivity, supports decentralized care, improves treatment initiation and clinical workflow |
|
|
Provides integrated POC molecular diagnostic solutions including real-time PCR and cartridge-based platforms | Reliable and reproducible results, supports rapid pathogen detection, compact and easy-to-use design, enables decentralized testing, enhances diagnostic efficiency and patient outcomes |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SEPSIS (Disease Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 10.5% from 2025 to 2030 |
| Largest Segment | RT-PCR (Technology) |
| Market Size Base Year (Billions) | ~USD 4.3 (2025) |
| Revenue Forecast (Billions) | ~USD 7.09 (2030) |
| Segments Covered | Product & Service, Technology, Sample Type, Application, End User, Disease Type |
6 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 34.5 | 36.8 | 39.6 | 43 | 47.2 | 52.4 | 58.6 | 66.1 | 10.8 |
| OTHER END USERS | 10.5 | 11 | 11.5 | 12.2 | 13 | 14.1 | 15.3 | 16.9 | 7.9 |
| PHYSICIANS' OFFICES/CLINICS | 27.5 | 29 | 30.8 | 33 | 35.8 | 39.2 | 43.1 | 48 | 9.3 |
| RESEARCH INSTITUTES | 3.6 | 3.7 | 3.8 | 4 | 4.2 | 4.5 | 4.8 | 5.2 | 6.4 |
| TOTAL | 76.1 | 80.5 | 85.7 | 92.2 | 100.2 | 110.1 | 121.8 | 136.2 | 9.7 |
Brazil's point-of-care molecular diagnostics market was valued at USD 51.7 million in 2025 and is expected to grow to USD 85.8 million by 2030.
Brazil's market is projected to grow at a compound annual growth rate (CAGR) of 10.7% from 2025 to 2030.
Key drivers include rising infectious disease prevalence, expanding healthcare coverage, government health initiatives, regulatory support, and demand for decentralized testing in remote areas of Brazil.
Brazil's regulatory framework has become increasingly conducive to rapid test deployment, particularly following pandemic-driven digital health adoption and government prioritization of diagnostic accessibility.
Brazil's urban centers and emerging regions are experiencing increased adoption, with particular focus on expanding access to remote and underserved areas through government health programs and private sector initiatives.
The study involved estimating activities to determine the current size of the point-of-care molecular diagnostics market. Exhaustive secondary research was done to collect information on the point-of-care molecular diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point-of-care molecular diagnostics market.
In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold-standard & silver-standard websites; regulatory bodies; and databases like D&B Hoovers, Bloomberg Business, and Factiva, were referred to identify and collect information for this study.
In the primary research process, primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown of Primaries
To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the point-of-care molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in tkehe mart. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Point-of-care molecular diagnostics includes various portable point-of-care devices and assays used by healthcare professionals to detect and diagnose diseases in humans using different techniques to identify and analyze nucleic acids or proteins at the molecular level.
Full forecast, segment splits, and company analysis for all Point-of-Care Molecular Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report